Compare CCCC & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCCC | SOPH |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.7M | 374.1M |
| IPO Year | 2020 | 2021 |
| Metric | CCCC | SOPH |
|---|---|---|
| Price | $4.17 | $4.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $12.20 | $7.50 |
| AVG Volume (30 Days) | ★ 2.9M | 84.6K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,947,000.00 | N/A |
| Revenue This Year | N/A | $23.09 |
| Revenue Next Year | N/A | $19.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $1.36 | $2.59 |
| 52 Week High | $4.60 | $5.70 |
| Indicator | CCCC | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 50.38 |
| Support Level | $2.13 | $4.54 |
| Resistance Level | N/A | $5.29 |
| Average True Range (ATR) | 0.37 | 0.27 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 70.09 | 67.02 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.